Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2004 Apr;48(4):1384-96.
doi: 10.1128/AAC.48.4.1384-1396.2004.

In vitro antimicrobial activity of doripenem, a new carbapenem

Yigong Ge  1 , Matthew A Wikler, Daniel F Sahm, Renée S Blosser-Middleton, James A Karlowsky
Affiliations
Comparative Study

In vitro antimicrobial activity of doripenem, a new carbapenem

Yigong Ge et al. Antimicrob Agents Chemother. 2004 Apr.

Abstract

The doripenem MICs at which 90% of the tested strains were inhibited ranged from 0.03 to 1 microg/ml for 10 species of Enterobacteriaceae (n = 351), from 0.03 to 0.12 microg/ml for oxacillin-susceptible staphylococci (n = 119), from 4 to 32 microg/ml for oxacillin-resistant staphylococci (n = 64), from < or =0.008 to 0.06 microg/ml for penicillin-susceptible streptococci (n = 132), and from 1 to 4 microg/ml for penicillin-resistant streptococci (n = 51). Overall, doripenem demonstrated in vitro activity similar to that of meropenem against gram-negative pathogens and to that of imipenem against gram-positive pathogens.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
MIC distributions of doripenem, ertapenem, imipenem, and meropenem against 211 isolates of ESBL-negative or ceftazidime-susceptible Enterobacteriaceae (A) and 140 isolates of ESBL-positive or ceftazidime-intermediate or ceftazidime-resistant Enterobacteriaceae (B).
FIG. 2.
FIG. 2.
MIC distributions of doripenem, ertapenem, imipenem, and meropenem against 42 isolates of oxacillin-susceptible S. aureus (A) and 23 isolates of oxacillin-resistant S. aureus (B).
FIG. 3.
FIG. 3.
MIC distributions of doripenem, ertapenem, imipenem, and meropenem against 44 isolates of penicillin-susceptible S. pneumoniae (A), 23 isolates of penicillin-intermediate S. pneumoniae (B), and 33 isolates of penicillin-resistant S. pneumoniae (C).
See this image and copyright information in PMC

References

    1. Iso, Y., T. Irie, Y. Nishino, K. Motokawa, and Y. Nishitani. 1996. A novel 1β-methylcarbapenem antibiotic, S-4661: synthesis and structure-activity relationships of 2-(5 substituted pyrrolidin-3-ylthio)-1β-methylcarbapenems. J. Antibiot. (Tokyo) 49:199-209. - PubMed
    1. Mori, M., M. Hikida, T. Nishihara, T. Nasu, and S. Mitsuhashi. 1996. Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I. J. Antimicrob. Chemother. 37:1034-1036. - PubMed
    1. Murray, P. R., E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.). 2003. Manual of clinical microbiology, 8th ed. ASM Press, Washington, D.C.
    1. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    1. National Committee for Clinical Laboratory Standards. 2003. Performance standards for antimicrobial susceptibility testing; thirteenth informational supplement, vol. 23. M100-S13. National Committee for Clinical Laboratory Standards, Wayne, Pa.

Publication types

MeSH terms